Cantor Fitzgerald Begins Coverage on Milestone Pharmaceuticals (NASDAQ:MIST)

Equities researchers at Cantor Fitzgerald began coverage on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research report issued to clients and investors on Thursday, MarketBeat reports. The firm set an “overweight” rating and a $3.00 price target on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 177.78% from the stock’s previous close.

Several other research firms also recently issued reports on MIST. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research report on Tuesday, July 14th. Finally, Wells Fargo & Company lowered their price target on Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.40.

Milestone Pharmaceuticals Price Performance

MIST stock opened at $1.08 on Thursday. The stock has a 50-day moving average price of $1.22 and a two-hundred day moving average price of $1.50. Milestone Pharmaceuticals has a 12-month low of $1.00 and a 12-month high of $3.06. The company has a current ratio of 8.13, a quick ratio of 7.92 and a debt-to-equity ratio of 3.25. The company has a market cap of $134.46 million, a PE ratio of -1.57 and a beta of 0.98.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The firm had revenue of $0.56 million during the quarter, compared to the consensus estimate of $0.82 million. As a group, research analysts predict that Milestone Pharmaceuticals will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Strategic Family Wealth Counselors L.L.C. acquired a new stake in Milestone Pharmaceuticals during the 4th quarter valued at $25,000. Eaton Financial Holdings Company LLC acquired a new position in Milestone Pharmaceuticals in the 4th quarter worth $26,000. Bank of America Corp DE boosted its position in Milestone Pharmaceuticals by 200,550.0% in the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after buying an additional 16,044 shares during the last quarter. Cetera Investment Advisers purchased a new position in Milestone Pharmaceuticals in the 4th quarter valued at about $42,000. Finally, Invesco Ltd. acquired a new stake in shares of Milestone Pharmaceuticals during the fourth quarter valued at about $44,000. 86.18% of the stock is currently owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.